PRIMARY STUDY

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria

Key Findings:  Subjects with type-2 diabetes and chronic kidney disease were given either aliskiren, a direct renin inhibitor, or amlodipine, a calcium-channel blocker (CCB). Results found that aliskiren had a significantly decreased percentage changes of urinary albumin/creatinine ratios, 8-OHdG and L-FABP levels compared with the CCB group, as did aldosterone levels, which strongly correlates with levels of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) and liver-type fatty acid-binding protein (L-FABP). Aliskiren presents a suitable and more effective alternative to increased doses of amlodipine in this patient population to reduce blood pressure and oxidative stress on the kidneys.